Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
Judith E Karp1, Jeffrey E Lancet21Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA; 2H. Lee Moffitt Comprehensive Cancer Center, Tampa, Florida, USAAbstract: Farnesyltransferase inhibitors (FTIs) represent a new class of signal t...
Guardado en:
Autores principales: | Judith E Karp, Jeffrey E Lancet |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a734bcadd2294080afe883a682fb06c3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bosutinib in the management of chronic myelogenous leukemia
por: Keller-von Amsberg G, et al.
Publicado: (2013) -
Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
por: Harnicar S, et al.
Publicado: (2014) -
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole J, et al.
Publicado: (2016) -
Cost-effectiveness of the regimen proposed by the International Consortium on Acute Promyelocytic Leukemia for the treatment of newly diagnosed patients with Acute Promyelocytic Leukemia
por: Sergio Rodríguez-Rodríguez, et al.
Publicado: (2021) -
Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
por: Lim MY, et al.
Publicado: (2014)